Search

  4. ProQR Announces Upcoming Presentation at RNA Editing Summit

    Press release

    LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will

  6. ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

    Press release

    LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will p

  8. ProQR Announces Year End 2023 Operating and Financial Results

    Press release

    Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinicAccelerated development of Axiomer™ for CNS ap

  9. ProQR Announces First Quarter 2025 Operating and Financial Results

    Press release

    … First Quarter 2025 Operating and Financial Results Axiomer™ ADAR-mediated RNA editing pipeline advancing across … transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its …